Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR5088905

—

4beb36a0-61c1-54fb-a310-98d271d55696

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.600
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
  • INFLAMMATORY_RESPONSE+0.600
  • ANGIOGENESIS+0.500
  • COMPLEMENT+0.500
  • IL6_JAK_STAT3_SIGNALING+0.500
  • COAGULATION+0.400
  • INTERFERON_GAMMA_RESPONSE+0.400
  • KRAS_SIGNALING_UP+0.400
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400

Top 10 suppressed

  • MYC_TARGETS_V2-0.700
  • E2F_TARGETS-0.600
  • G2M_CHECKPOINT-0.600
  • MYC_TARGETS_V1-0.600
  • MITOTIC_SPINDLE-0.500
  • UNFOLDED_PROTEIN_RESPONSE-0.500
  • DNA_REPAIR-0.400
  • WNT_BETA_CATENIN_SIGNALING-0.300
  • MTORC1_SIGNALING-0.200
  • OXIDATIVE_PHOSPHORYLATION-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR5088904
melanoma-umap@29
——0.976
2SRR5088928
melanoma-umap@29
——0.951
3ERR2598319
medullo-epn-umap@date-based
fetalfetal0.942
4MDT-AP-0484
medullo-epn-umap@date-based
MedMedulloblastoma0.940
5SAMN03290935
melanoma-umap@29
——0.939
6TCGA-A2-A0EN-01A-13R-A084-07
breast-umap@18
—A0.936
7sclc0617_S65.txt
lung-landscapes@6
—cohortMD20.932
8MDT-AP-1254
medullo-epn-umap@date-based
MedMedulloblastoma0.929
9SRR5088860
melanoma-umap@29
——0.928
10ERR2598337
medullo-epn-umap@date-based
fetalfetal0.920

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.600Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.600Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.600Idelalisib— uncovered
ANGIOGENESIS0.500Remibrutinib— uncovered
COMPLEMENT0.500Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
COAGULATION0.400Binimetinib— uncovered
INTERFERON_GAMMA_RESPONSE0.400Idelalisib— uncovered
KRAS_SIGNALING_UP0.400Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.400Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.400Inavolisib— uncovered
HYPOXIA0.300Idelalisib— uncovered
IL2_STAT5_SIGNALING0.300Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.300Inavolisib— uncovered
MYOGENESIS0.300Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.300Inavolisib— uncovered
APICAL_JUNCTION0.200Inavolisib— uncovered
APOPTOSIS0.200Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.200Idelalisib— uncovered
KRAS_SIGNALING_DN0.200Remibrutinib— uncovered